RetinalGenix Technologies Company Description
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders.
Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians.
It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer’s syndrome dementia.
The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
| Country | United States |
| Founded | 2017 |
| Industry | Medical Devices |
| Sector | Healthcare |
| CEO | Jerry Katzman |
Contact Details
Address: 409 Apollo Beach Boulevard Apollo Beach, Delaware 33572 United States | |
| Phone | 415 578 9583 |
| Website | retinalgenix.com |
Stock Details
| Ticker Symbol | RTGN |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US76133Y1055 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jerry Katzman | Chief Executive Officer, President, Interim Chief Financial Officer and Chairman |